Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise. [ADVOCATE AJAY AMITABH SUMAN, EMAIL: ajayamitabh7@gmail.com, Mob:09990389539]
Thursday, March 21, 2024
Novozymes Vs Assistant Controller of Patent
Immunas Pharma, Inc. Vs Assistant Controller of Patent
Abstract:
A legal case concerning the rejection of a patent application under Section 3(c) of the Patent Act, 1970 has been discussed herein. The case revolves around Indian Patent Application No.5542/CHENP/2010, which sought protection for an invention titled "Antibody Capable of Binding Specifically to A-beta Oligomer and Use Thereof."
The rejection was based on the argument that the claimed antibody, with specific amino acid sequences, was inherent and naturally occurring. However, the appellate authority overturned the decision, emphasizing the engineered nature of the antibody. This article examines the legal and technical intricacies of the case, highlighting the interpretation and application of Section 3(c) in patent law.
Introduction:
Section 3(c) of the Patent Act, 1970, serves as a crucial provision governing the patentability of inventions. It stipulates that inventions that are mere discoveries of a scientific principle or naturally occurring substances are not patentable. This provision aims to prevent the monopolization of naturally occurring phenomena and encourage genuine innovation. However, its interpretation and application in specific cases often present challenges, as demonstrated in the case under review.
Legal Framework:
Under Section 3(c) of the Patent Act, inventions concerning substances occurring naturally are not patentable unless they are produced by means of a technical process involving human intervention, resulting in a substance not naturally occurring. This provision aims to strike a balance between promoting innovation and preventing the patenting of discoveries that merely reflect natural phenomena.
Case Analysis:
The case at hand involves a patent application for an antibody capable of binding specifically to A-beta oligomers. The application was rejected on the grounds that the claimed antibody, with specific amino acid sequences, was considered inherent and naturally occurring, falling under the ambit of Section 3(c). However, the appellant contested this decision, arguing that the antibody was engineered through a sophisticated process involving human intervention.
Technical Analysis:
From a technical standpoint, the appellant's argument holds weight. The antibody in question was not merely isolated from a natural source but was engineered using a series of deliberate steps. The process involved injecting an engineered antigen into mice, followed by the fusion of lymph material extracted from the mice with myeloma cells through the hybridoma process.
This resulted in the production of the antibody claimed in the patent application. The deliberate manipulation of biological materials through human intervention distinguishes the claimed invention from naturally occurring substances, aligning it with the requirements of patentability.
Conclusion:
The appellate authority's decision to overturn the rejection of the patent application under Section 3(c) underscores the importance of human intervention in the patentability of biological inventions. While Section 3(c) aims to prevent the patenting of naturally occurring substances, it does not preclude inventions that involve significant human intervention and technical processes.
Case Title: Immunas Pharma, Inc. Vs Assistant Controller of Patent
Order Date: 06.03.2024
Case No. (OA/22/2018/PT/CHN)
Neutral Citation:2024.MHC.1144
Name of Court: High Court of Madras
Name of Hon'ble Judge: Senthilkumar Ramamoorthy, H.J.
Disclaimer:
This article is meant for informational purposes only and should not be construed as substitute for legal advice as Ideas, thoughts, views, information, discussions and interpretation perceived and expressed herein are are subject to my subjectivity and may contain human errors in perception, interpretation and presentation of the fact and issue of law involved herein.
Written By: Advocate Ajay Amitabh Suman,
IP Adjutor - Patent and Trademark Attorney,
Email: ajayamitabhsuman@gmail.com,
Ph No: 9990389539
Audertec SolutionsVs Controller General of Patents Designs
Abstract:
This article discusses the legal and technical aspects surrounding the test of obviousness in patent applications, using a recent case study concerning a patent application for a method and system for detecting road anomalies.
The case highlights the challenges patent applicants face when establishing the inventive step of their invention vis-à-vis prior art references. Through a detailed analysis of the legal framework and technical nuances involved, this article aims to provide insights into the application of the obviousness test in patent law.
Introduction:
The patent system is designed to incentivize innovation by granting exclusive rights to inventors for a limited period. However, to be granted a patent, an invention must meet certain criteria, including novelty, utility, and non-obviousness.
The test of obviousness, also known as inventive step, plays a crucial role in determining the patentability of an invention. This article focuses on a specific case where a patent application for road anomaly detection technology was rejected on the grounds of obviousness vis-à-vis prior art.
Legal Framework:
Under the Patents Act, 1970, Section 2(1)(ja) defines invention as a new product or process involving an inventive step and capable of industrial application. Section 2(1)(ja) further elucidates that an inventive step involves a feature of an invention that involves technical advancement compared to existing knowledge or having economic significance or both, and that makes the invention not obvious to a person skilled in the art.
The determination of inventive step is primarily based on the prior art, which includes any information that has been made available to the public before the priority date of the invention.
Case Analysis:
In the case at hand, the patent application for a method and system for detecting road anomalies was rejected on the grounds of obviousness vis-à-vis a prior art reference referred to as D-2.
The applicant argued that there were significant differences between the subject matter patent application and D-2, including the placement of the camera, coverage area, and method of data analysis.
However, the appellate authority dismissed the appeal, concluding that the features claimed in the subject matter patent were already envisioned in the complete specifications of D-2.
Conclusion:
The case study exemplifies the complexities involved in assessing the obviousness of an invention in patent applications. While the prior art may disclose similar features or functionalities, it is essential to consider the technical advancements and inventive contributions claimed by the applicant.
In cases where the differences between the invention and the prior art not substantial and does result in technical advancement, patent protection should not be granted.
Case Title: Audertec SolutionsVs Controller General of Patents Designs
Order Date: 01.03.2024
Case No. C.A.(COMM.IPD-PAT) 3/20
Neutral Citation:01.03.2024
Name of Court: High Court of Delhi
Name of Hon'ble Judge : C Harishankar, H.J.
Disclaimer:
This article is meant for informational purposes only and should not be construed as substitute for legal advice as Ideas, thoughts, views, information, discussions and interpretation perceived and expressed herein are are subject to my subjectivity and may contain human errors in perception, interpretation and presentation of the fact and issue of law involved herein.
Written By: Advocate Ajay Amitabh Suman,
IP Adjutor - Patent and Trademark Attorney,
Email: ajayamitabhsuman@gmail.com,
Ph No: 9990389539
Wednesday, March 20, 2024
Association of Indian Magazines Vs Union of India
Amit Lalit Kumar Aswani Vs Sunil Chelani
Friday, March 15, 2024
Snpc Machines Private Limited Vs Mr Vishal Choudhary
Bloomberg Television Production Services India Pvt. Ltd. Vs Zee Entertainment Enterprises Limited
Rong Thai International Group Company Limited Vs Ena Footwear Private Limited
Thursday, March 14, 2024
Novartis Ag Vs Natco Pharma Limited and another
Introduction:
The realm of patent law is characterized by a delicate balance between
fostering innovation and ensuring that patents are granted on meritorious
grounds. Central to this balance is the mechanism of pre-grant opposition,
designed to facilitate a rigorous examination of patent applications. This
article delves into the nuanced legal principles governing pre-grant
opposition, emphasizing its facilitation role in the examination
process and delineating its limitations.
The Division Bench, High Court of Delhi , Comprising of Hon'ble Judges
namely Shri Yashwant Varma and Shri Dharmesh Sharma was having an occasion to
answer this issue while passing the Judgement dated 09.01.2024 in Appeal
bearing LPA No. 50 of 2023 titled as Novartis Ag Vs Natco Pharma Limited and
another, delved into the critical examination of the order dated 14.12.2022
passed by controller of Patent , which allowed certain amendments and
ultimately resulted in grant of Indian Patent. IN414518. This grant of Patent
to Novartis subsequently led to litigation. The Hon'ble Division Bench, High
Court of Delhi rejected the argument of the pre grant Opponent that the same
had any right to be heard in Patent Examination process. Thereby affirmed
the order of controller , granting the subject matter Patent.
Background:
Novartis AG was the Applicant of the subject matter patent IN‘518,
originated from PCT application no. PCT/US2006/043710 dated 08.11.2006, which
was filed as Indian national phase application bearing no. 4412/DELNP/2007 on
08.06.2007 before the Controller of Patents. Natco and few other entities were
pre grant opponent. The subject matter order dated 14.12.2022 passed by
the controller which resulted in filing of the subject matter writ and
subsequent thereto the present Letters Patent Appeal , whereby certain
amendments in Indian Patent Application No. IN4145 were allowed without
granting any opportunity to pre grant opponent , to be heard.
The crux of the controversy lies in the alleged violation
of the principles of natural justice. The opponent contended that the order
permitting amendments to the patent application was issued without granting
them a fair hearing. Specifically, all five pre-grant opposition hearings had
concluded on 03 November 2022. Despite this, the Controller of Patents directed
the applicant to carry out amendments, which were eventually allowed on
14.12.2022.
The Core Legal Question:
The pivotal issue at hand is whether an opponent possesses the right to
participate in the patent examination process, especially when amendments are
under consideration. Stated differently, does the opponent have a stake in the
examination process, mandating their participation when modifications to the
patent application are being evaluated?
Judicial Interpretation:
The Hon'ble Division Bench's ruling provided a nuanced
interpretation of the relevant legal provisions. According to Rule 55(5), the
right of hearing is primarily associated with the adjudication and disposal of
the representation for opposition. The court opined that conferring an
opportunity for a hearing at the representation stage does not automatically
translate to an inherent right for the opponent to participate in Patent
examination process.
Furthermore, the court elucidated that while pre-grant opposition
undoubtedly aids the Controller in decision-making, it does not ipso facto
grant opponents an inherent right to participation or an audience during the
Patent examination process. This interpretation upholds the procedural autonomy
of the Controller in conducting examinations while balancing the interests of
both applicants and opponents.
Implications:
it is imperative
to understand that the representation for opposition is not inherently
adversarial or contentious. Instead, its primary objective is to aid and
facilitate the examination of the patent application. This facilitative role
underscores the constructive intent behind pre-grant opposition, which aims to
ensure that patents are granted based on valid and meritorious grounds.
The scope and
limitations of pre-grant opposition are circumscribed by Section 25(1) of the
relevant statute. This provision specifies the grounds on which opposition can
be raised, thereby confining the opposition's ambit to statutory parameters.
Consequently, any challenge raised by an opponent must align with the grounds
delineated in Section 25(1), ensuring that the opposition remains tethered to
statutory constraints.
The Division Bench's interpretation provides clarity on the locus of a
pre-grant patent opponent within the patent examination framework. By
distinguishing between the stages where opponents have a right to be heard,
such as during pre-grant opposition, and stages where their participation is
not mandated, the court ensures a balanced and efficient patent examination
process.
The Concluding Note:
Pre-grant
opposition serves a pivotal yet circumscribed role in the patent examination
landscape. Its facilitative nature aims to aid the Controller in conducting a
holistic examination of patent applications, ensuring adherence to statutory
criteria and principles of natural justice. However, this role is not without
limitations, as evidenced by the Court's observations emphasizing the pre grant
opponent's restricted right to intervene in the process of grant of Patent only
by way of pre grant opposition , however the same has no right to be heard in
examination process of the Patent, which is solely the domain between
Controller of Patent and the Applicant for Patent.
The Case Law Discussed:
Case Title:
Novartis Ag Vs Natco Pharma Limited and another
Date of
Judgement/Order:09.01.2024
Case No. LPA
50/2023
Neutral
Citation: 2023:DHC:84:DB
Name of Hon'ble
Court: Delhi High Court
Name of Hon'ble
Judge: Yashwant Varma+Dharmesh Sharma, H.J.
Disclaimer:
Ideas, thoughts, views, information, discussions and interpretation expressed
herein are being shared in the public Interest. Readers' discretion is advised
as these are subject to my subjectivity and may contain human errors in
perception, interpretation and presentation of the fact and issue involved
herein.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor -
Patent and Trademark Attorney, Email: ajayamitabhsuman@gmail.com, Ph No:
9990389539
Introduction:
The realm of patent law is characterized by a delicate balance between
fostering innovation and ensuring that patents are granted on meritorious
grounds. Central to this balance is the mechanism of pre-grant opposition,
designed to facilitate a rigorous examination of patent applications. This
article delves into the nuanced legal principles governing pre-grant
opposition, emphasizing its facilitation role in the examination
process and delineating its limitations.
The Division Bench, High Court of Delhi , Comprising of Hon'ble Judges
namely Shri Yashwant Varma and Shri Dharmesh Sharma was having an occasion to
answer this issue while passing the Judgement dated 09.01.2024 in Appeal
bearing LPA No. 50 of 2023 titled as Novartis Ag Vs Natco Pharma Limited and
another, delved into the critical examination of the order dated 14.12.2022
passed by controller of Patent , which allowed certain amendments and
ultimately resulted in grant of Indian Patent. IN414518. This grant of Patent
to Novartis subsequently led to litigation. The Hon'ble Division Bench, High
Court of Delhi rejected the argument of the pre grant Opponent that the same
had any right to be heard in Patent Examination process. Thereby affirmed
the order of controller , granting the subject matter Patent.
Background:
Novartis AG was the Applicant of the subject matter patent IN‘518,
originated from PCT application no. PCT/US2006/043710 dated 08.11.2006, which
was filed as Indian national phase application bearing no. 4412/DELNP/2007 on
08.06.2007 before the Controller of Patents. Natco and few other entities were
pre grant opponent. The subject matter order dated 14.12.2022 passed by
the controller which resulted in filing of the subject matter writ and
subsequent thereto the present Letters Patent Appeal , whereby certain
amendments in Indian Patent Application No. IN4145 were allowed without
granting any opportunity to pre grant opponent , to be heard.
The crux of the controversy lies in the alleged violation
of the principles of natural justice. The opponent contended that the order
permitting amendments to the patent application was issued without granting
them a fair hearing. Specifically, all five pre-grant opposition hearings had
concluded on 03 November 2022. Despite this, the Controller of Patents directed
the applicant to carry out amendments, which were eventually allowed on
14.12.2022.
The Core Legal Question:
The pivotal issue at hand is whether an opponent possesses the right to
participate in the patent examination process, especially when amendments are
under consideration. Stated differently, does the opponent have a stake in the
examination process, mandating their participation when modifications to the
patent application are being evaluated?
Judicial Interpretation:
The Hon'ble Division Bench's ruling provided a nuanced interpretation of the relevant legal provisions. According to Rule 55(5), the right of hearing is primarily associated with the adjudication and disposal of the representation for opposition. The court opined that conferring an opportunity for a hearing at the representation stage does not automatically translate to an inherent right for the opponent to participate in Patent examination process.
Furthermore, the court elucidated that while pre-grant opposition
undoubtedly aids the Controller in decision-making, it does not ipso facto
grant opponents an inherent right to participation or an audience during the
Patent examination process. This interpretation upholds the procedural autonomy
of the Controller in conducting examinations while balancing the interests of
both applicants and opponents.
Implications:
it is imperative to understand that the representation for opposition is not inherently adversarial or contentious. Instead, its primary objective is to aid and facilitate the examination of the patent application. This facilitative role underscores the constructive intent behind pre-grant opposition, which aims to ensure that patents are granted based on valid and meritorious grounds.
The scope and limitations of pre-grant opposition are circumscribed by Section 25(1) of the relevant statute. This provision specifies the grounds on which opposition can be raised, thereby confining the opposition's ambit to statutory parameters. Consequently, any challenge raised by an opponent must align with the grounds delineated in Section 25(1), ensuring that the opposition remains tethered to statutory constraints.
The Division Bench's interpretation provides clarity on the locus of a pre-grant patent opponent within the patent examination framework. By distinguishing between the stages where opponents have a right to be heard, such as during pre-grant opposition, and stages where their participation is not mandated, the court ensures a balanced and efficient patent examination process.
The Concluding Note:
Pre-grant
opposition serves a pivotal yet circumscribed role in the patent examination
landscape. Its facilitative nature aims to aid the Controller in conducting a
holistic examination of patent applications, ensuring adherence to statutory
criteria and principles of natural justice. However, this role is not without
limitations, as evidenced by the Court's observations emphasizing the pre grant
opponent's restricted right to intervene in the process of grant of Patent only
by way of pre grant opposition , however the same has no right to be heard in
examination process of the Patent, which is solely the domain between
Controller of Patent and the Applicant for Patent.
The Case Law Discussed:
Case Title: Novartis Ag Vs Natco Pharma Limited and another
Date of Judgement/Order:09.01.2024
Case No. LPA
50/2023
Neutral
Citation: 2023:DHC:84:DB
Name of Hon'ble
Court: Delhi High Court
Name of Hon'ble
Judge: Yashwant Varma+Dharmesh Sharma, H.J.
Disclaimer:
Ideas, thoughts, views, information, discussions and interpretation expressed
herein are being shared in the public Interest. Readers' discretion is advised
as these are subject to my subjectivity and may contain human errors in
perception, interpretation and presentation of the fact and issue involved
herein.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor -
Patent and Trademark Attorney, Email: ajayamitabhsuman@gmail.com, Ph No:
9990389539
Blog Archive
- January 2025 (30)
- October 2024 (8)
- September 2024 (34)
- August 2024 (68)
- July 2024 (39)
- June 2024 (57)
- May 2024 (49)
- April 2024 (6)
- March 2024 (44)
- February 2024 (39)
- January 2024 (21)
- December 2023 (29)
- November 2023 (23)
- October 2023 (29)
- September 2023 (33)
- August 2023 (29)
- July 2023 (29)
- June 2023 (2)
- May 2023 (1)
- April 2023 (5)
- March 2023 (6)
- February 2023 (1)
- November 2022 (17)
- October 2022 (11)
- September 2022 (30)
- August 2022 (47)
- July 2022 (37)
- June 2022 (26)
- October 2020 (1)
- September 2020 (1)
- April 2020 (1)
- March 2020 (1)
- February 2020 (2)
- December 2019 (1)
- September 2019 (3)
- August 2019 (2)
- July 2019 (1)
- June 2019 (2)
- April 2019 (3)
- March 2019 (2)
- February 2019 (2)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (2)
- September 2018 (2)
- August 2018 (8)
- July 2018 (2)
- June 2018 (1)
- May 2018 (41)
- April 2018 (7)
- March 2018 (3)
- February 2018 (4)
- January 2018 (2)
- December 2017 (6)
- November 2017 (4)
- September 2017 (5)
- August 2017 (6)
- July 2017 (1)
- June 2017 (1)
- May 2017 (10)
- April 2017 (16)
- November 2016 (3)
- October 2016 (24)
- March 2015 (2)
- January 2014 (1)
- December 2013 (4)
- October 2013 (2)
- September 2013 (7)
- August 2013 (27)
- May 2013 (7)
- September 2012 (31)
- December 2009 (3)
- September 2009 (1)
- March 2009 (3)
- January 2009 (2)
- December 2008 (1)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
$~5 * IN THE HIGH COURT OF DELHI AT NEW DELHI + FAO 317/2018, CAV 617/2018 & CM AP...
-
==================== Judgement Date:29.08.2022 Case No. CM (M) IPD 2 of 2022 Hon'ble High Court of Delhi Prathiba M Singh, H.J. Institu...
My Blog List
-
मछलियों में घड़ियाल - गीता-विभूति योग श्रीभगवानुवाच “प्रह्लादश्चास्मि दैत्यानां कालः कलयतामहम्। मृगाणां च मृगेन्द्रोऽहं वैनतेयश्च पक्षिणाम्।।” मैं दैत्यों में प्रह्लाद और ग...2 weeks ago
-
Deepfake Technology: Unveiling The Challenges And Protective Measures - Introduction: The rapid evolution of technology has propelled humanity into an era of unprecedented progress and connectivity. However, as with any doubl...1 year ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री